Our Website Uses Cookies 

We and the third parties that provide content, functionality, or business services on our website may use cookies to collect information about your browsing activities in order to provide you with more relevant content and promotional materials, on and off the website, and help us understand your interests and improve the website.

For more information, please contact us or consult our Privacy Notice.

Your binder contains too many pages, the maximum is 40.

We are unable to add this page to your binder, please try again later.

This page has been added to your binder.

John Hurvitz co-chairs Covington's Life Sciences Industry Group, heads the firm's Technology Transactions Group and is vice-chair of the firm’s Corporate Group.

Mr. Hurvitz is a trusted advisor to both established and emerging life sciences companies, providing not only transactional counsel but also strategic advice with respect to business development, asset management, performance enhancement, dispute resolution under existing collaborations, industry best practices and other benchmarking advice.  His clients and deal experience extend throughout the United States, Europe and Asia as well to emerging markets and include all segments of the industry—pharma, biotech, medtech, diagnostics, animal health, vaccines and health services.

  • Merck in connection with the sale of its Consumer Care Business to Bayer AG for $14.2 billion. 
  • AbbVie in a novel collaboration with the Google-backed life sciences start-up company Calico focused on aging and age-related diseases, such as cancer and neurodegenerative diseases.
  • Regeneron in an agreement with Bayer Healthcare to jointly develop an innovative antibody for the treatment of wet age-related macular degeneration (wet AMD), the leading cause of blindness in the elderly.
  • Millennium: The Takeda Oncology Company in a collaboration agreement with Mersana to develop next-generation antibody-drug conjugates (ADCs) using Mersana’s proprietary Fleximer technology.
  • AstraZeneca in its global agreement with Pfizer to switch AstraZeneca’s blockbuster GI drug, Nexium, to over-the-counter, which involved an upfront payment of $250 million as well a right of first refusal to switch another of AstraZeneca’s Rx Products.
  • Eli Lilly in its agreement to terminate its alliance with Amylin Pharmaceuticals for Byetta and Bydureon and to resolve the outstanding litigation between the companies, involving a two-year transition of responsibilities outside the US and payments of up to $1.6 billion.
  • AstraZeneca in an agreement with Moderna Therapeutics to develop and commercialize pioneering messenger RNA therapeutics for the treatment of serious cardiovascular, metabolic, and renal diseases, as well as cancer, which involved an upfront payment of $240 million and up to an additional $180 million in technical milestones.
  • Eisai in an agreement with Epizyme and Roche Molecular Systems to collaborate on the development of a companion diagnostic to advance personalized therapeutics for patients with lymphomas possessing genetic mutations in the epigenetic enzyme EZH2.
  • Takeda in its acquisition of Intellikine, a privately-held company focused on the discovery and development of innovative, small molecule drugs, for $190 million at closing and up to $120 million in additional potential clinical development milestone payments.
  • AstraZeneca in its agreement with Ironwood Pharmaceuticals, Inc. to develop and market Ironwood’s linaclotide in China.
  • AstraZeneca in its strategic diabetes alliance with Bristol-Myers Squibb in connection with BMS’s acquisition of Amylin Pharmaceuticals in a deal valued at $7 billion (approximately half the cost of which was borne by AZ).
  • Abbott Laboratories in its $3.7 billion acquisition of Kos Pharmaceuticals, Inc.
  • Medarex on its $2.4 billion merger with Bristol-Myers Squibb.
  • King Pharmaceuticals in its $3.6 billion merger with Pfizer Inc.
  • Boehringer Ingelheim Vetmedica in its acquisition of certain animal health products divested by Wyeth and Pfizer Inc. pursuant to an FTC consent order entered into in connection with Pfizer Inc.’s acquisition of Wyeth.

Pro Bono

  • Advisor, World Bank and Global Alliance for Vaccines and Immunization (GAVI) in their efforts on behalf of the G7/8 to develop and implement a pilot Advance Market Commitment (AMC) to stimulate the development and introduction of new vaccines to address critical unmet health needs in the developing world, such as HIV/AIDS, malaria and tuberculosis.
  • Member, Expert Group on AMCs convened by the World Bank and GAVI to advise on the design and implementation of an AMC pilot project.
  • Member, Global Health Forecasting Working Group, convened by the Policy Research Network at the Center for Global Development to analyze demand forecasting for health products, with a particular emphasis on products that are procured largely with external funding, to identify areas for improvement and to develop analytically-based policy recommendations.
  • Outside Counsel, Global HIV Vaccine Enterprise. Assisting the Enterprise with corporate structure, governance and other matters.
  • Outside Counsel, Zero to Three, a national non-profit organization dedicated to promoting the healthy development of infants and toddlers by supporting and strengthening families, communities, and those who work on their behalf.
  • Legal Advisor, Consortium for Child Welfare, the association of the non-governmental child welfare organizations serving the District of Columbia. Represented the Consortium in its efforts to overhaul the child welfare laws and create a dedicated family division within the Superior Court in the District of Columbia.
  • On behalf of the District of Columbia Bar’s Community Economic Development Project, prepared a comprehensive legal practice and issues manual for non-profit day care centers and provided training for attorneys who agreed to represent non-profit day care centers on a pro bono basis so as to help stimulate the creation of high quality, affordable day care in the District of Columbia for low- and moderate-income families.
  • Legal Advisor, Housing and Urban Development Occupancy Task Force on People with Disabilities in Public Housing. Advised the Task Force in connection with its efforts to improve access to public housing and related services for people with mental illness and developmental disabilities.
  • On behalf of the Lawyer’s Committee for Civil Rights, successfully represented a multi-ethnic group of highly prominent Bosnian citizens in their efforts to obtain political asylum in the United States at the height of the war in Bosnia-Herzegovina.

Memberships and Affiliations

  • Haverford College, member of the Corporation

Previous Experience

  • Salomon Brothers, Mergers, Acquisitions and Divestitures Group, Financial Analyst
  • Georgetown University Law Center, Food and Drug Law, Adjunct Professor
  • The National Law Journal, “Healthcare and Life Sciences Trailblazers” (2020)
  • Chambers USA, recognized for Life Sciences Corporate/Commercial (Band 1)
  • Chambers Global, recognized as a leading lawyer for Life Sciences Corporate/Commercial
  • Washington DC Super Lawyers   
  • Best Lawyers in America, recognized for FDA
  • Law360, Life Sciences “MVP”   
  • Who's Who Legal, Life Sciences – Transactional
  • Legal 500 US, “Leading Lawyer” – Healthcare: Life Sciences
  • Legal 500 US, M&A - Commercial Deals and Contracts (2016)
  • Legal 500 US, Patents - Portfolio Management and Licensing (2016)
  • PLC Which Lawyer?, consistently recognized as a "leading commercial and partnering" lawyer, and one of only five "leading" corporate partnering lawyers in the US.
  • LMG Life Sciences, “Life Science Star”
  • IAM Patent 1000 - The World’s Leading Patent Practitioners